SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.

For decades, the dominant treatment approaches for substance use disorder have centered around identifying past deficits and unpacking trauma. SFT offers a compelling alternative.

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

With a focus on cutting-edge vision therapy, progressive myopia management and full-scope comprehensive eye care, a new name ...

They don't realize that something is not right," said Katie. She eventually had him evaluated at Wow Vision Therapy in St. Joseph. As it turns out, Jesse's struggles with reading fluency ...

OTUS Launches in the U.S. as a Smart Vision Training Solution for Modern Vision Therapy Centers. Built for professionals, OTUS enables more efficient and precise accommodative training through AI ...

While recent advancements in retinal disease treatments have successfully slowed disease progression, no effective therapy has been developed to restore already lost vision -- until now.

While recent advancements in retinal disease treatments have successfully slowed disease progression, no effective therapy has been developed to restore already lost vision—until now.

The extraordinary potential of gene therapy brings important discussions about healthcare accessibility. While these treatments offer unprecedented possibilities for vision restoration ...

Jan. 7, 2025 – A new light therapy device could be a game-changer for millions at risk of vision loss. The FDA has approved a first-of-its-kind treatment for dry age-related macular ...